Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

NCT03199885 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03199885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03199885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Terminated
Start date
April 5, 2019
Completion date
April 4, 2025
Enrollment
190 (actual)
Sites
673

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast adenocarcinoma, metastatic her2-positive breast carcinoma, recurrent breast adenocarcinoma, recurrent her2-positive breast carcinoma, stage iii breast cancer ajcc v7, stage iv breast cancer ajcc v6 and v7, unresectable breast carcinoma, unresectable her2-positive breast carcinoma